Thoracic Oncology
Clinical research includes advanced non-small cell lung cancer, with attention to tumours carrying EGFR mutations, ALK rearrangements, and ROS1 fusions after targeted treatment.
- Platinum-based chemotherapy
- Pemetrexed
- Atezolizumab
- Bevacizumab
The sponsor also funds research relevant to treatment selection in adenocarcinoma and biomarker-defined lung cancer populations.
Thyroid Cancer
Work in differentiated thyroid cancer focuses on patients in the intermediate-risk category, especially those considered low-risk within that group.
- Radioiodine treatment
- Post-operative assessment
- Serum thyroglobulin
- Diagnostic scintigraphy
These studies address treatment decisions after surgery and the role of radioiodine in tailoring care.
Gastrointestinal Oncology
The sponsor supports perioperative research in resectable gastric cancer, with interest in tumour response before definitive surgery.
- FLOT chemotherapy
- Spartalizumab
- Pre-operative treatment
- Pathologic response
Its portfolio in this area reflects involvement in combined immunotherapy and cytotoxic treatment strategies for upper gastrointestinal malignancy.
Genitourinary Oncology
Research activity spans urothelial carcinoma and clear-cell renal cell carcinoma, including maintenance approaches and treatment monitoring in advanced disease.
- TALazoparib
- Avelumab
- Cabozantinib
- Nivolumab
Studies also examine digital symptom monitoring and patient-reported outcomes in kidney cancer care.
Neuro-Oncology
Clinical trials include glioblastoma and other high-grade gliomas, with interest in treatment approaches for unresectable disease.
- Radiotherapy
- Olaparib
- Temozolomide
- High-grade glioma
This area reflects involvement in combined modality treatment for aggressive central nervous system tumours.
